Genscript Biotech Management
Management criteria checks 1/4
Genscript Biotech's CEO is Sherry Shao, appointed in Jul 2021, has a tenure of 4.33 years. total yearly compensation is $3.62M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 0.056% of the company’s shares, worth HK$18.49M. The average tenure of the management team and the board of directors is 4.3 years and 2.7 years respectively.
Key information
Sherry Shao
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 9.74% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.06% |
| Management average tenure | 4.3yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
Nov 03
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Oct 10We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
Sep 18Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
Sep 08Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Jul 29At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Jul 24
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
May 14Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Apr 07Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Feb 12Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 20Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$5m |
| Mar 31 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$4m | US$352k | -US$67m |
| Jun 30 2024 | n/a | n/a | US$419m |
| Mar 31 2024 | n/a | n/a | US$421m |
| Dec 31 2023 | US$2m | US$353k | US$423m |
Compensation vs Market: Sherry's total compensation ($USD3.62M) is above average for companies of similar size in the Hong Kong market ($USD629.26K).
Compensation vs Earnings: Sherry's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Sherry Shao (45 yo)
Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.3yrs | US$531.00k | 0.015% HK$ 4.9m | |
| CEO & COO | 4.3yrs | US$3.62m | 0.056% HK$ 18.5m | |
| Co-Founder | 23.8yrs | US$914.00k | 0.037% HK$ 12.2m | |
| Co-Founder & Executive Director | 2.9yrs | US$611.00k | no data | |
| Chief Strategy Officer & Executive Director | 5yrs | US$384.00k | 0.047% HK$ 15.7m | |
| Interim CFO & VP of Finance | less than a year | no data | no data | |
| General Counsel & Chief Compliance Officer | no data | no data | no data | |
| Head of Corporate Communications | no data | no data | no data | |
| Chief Marketing Officer for GenScript Life Science Group | 1yr | no data | no data | |
| Head of Global Diversity | no data | no data | no data | |
| Head of Sustainability | no data | no data | no data | |
| Company Secretary | 10.3yrs | no data | no data |
Experienced Management: 1548's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.3yrs | US$531.00k | 0.015% HK$ 4.9m | |
| Co-Founder | 10.5yrs | US$914.00k | 0.037% HK$ 12.2m | |
| Co-Founder & Executive Director | 3.5yrs | US$611.00k | no data | |
| Chief Strategy Officer & Executive Director | 5yrs | US$384.00k | 0.047% HK$ 15.7m | |
| Independent Non-executive Director | 1.2yrs | US$23.00k | no data | |
| Member of Advisory Board | 1.8yrs | no data | no data | |
| Member of Advisory Board | 6.2yrs | no data | no data | |
| Independent Non-Executive Director | 1.2yrs | US$30.00k | no data | |
| Member of Scientific Advisory Board | 1.7yrs | no data | no data | |
| Independent Non-Executive Director | 7yrs | US$86.00k | 0.00043% HK$ 142.6k | |
| Independent Non-Executive Director | 1.6yrs | US$60.00k | no data | |
| Independent Non-Executive Director | 1.6yrs | US$60.00k | no data |
Experienced Board: 1548's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 02:46 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genscript Biotech Corporation is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |